Read the latest article published in OnDrugDelivery about the current challenges faced by the topical spray-based delivery of therapeutics. And how our Ad-Mist™ spray nozzle overcomes these challenges to harness the potential of this delivery route.

JBT HubUp alliance has celebrated its 5th anniversary and exhibited at the international CPHI exhibition in Frankfurt (Germany), 1-3 November 2022.

EVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and advanced therapy drugs to neonates.

EVEON is exploring the Asian medical device market, including South Korea and Japan, as part of the French Healthcare Booster.

Our medical device Intuity® Spray received an award at the Pharmapack 2021 exhibition in the exhibitor - administration mode category.

EVEON has developed Ad-Mist™, an airless spray nozzle that can be used to produce fine droplets in the form of a mist. 

EVEON has signed a collaboration agreement with BEPATIENT to produce patient-centric digital solutions that serve both clinical research and digital therapeutics applications.

EVEON is proposing to automate and deliver multidose drugs from a vial, as well as vaccines used in the context of the Covid-19 pandemic.

EVEON celebrated its 10th anniversary and is ranked by Forbes as the 3rd most inventive French company in the medical technologies category.

The presentation of the DIPSA project, needle-free piezoelectric injection device, to the Auvergne Rhone Alpes region, as part of the call for R&D booster projects, received a favourable opinion in March 2019. The project was launched on Tuesday, April 15, 2019, at Cedrat Technologies (CTEC), project coordinator, with EVEON, as industrial partner, and the Grenoble Rheology and Processes Laboratory (LRP).